BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16510328)

  • 21. Ovary removal is linked to lower breast cancer mortality in BRCA1 carriers.
    Wise J
    BMJ; 2015 Apr; 350():h2182. PubMed ID: 25911348
    [No Abstract]   [Full Text] [Related]  

  • 22. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 23. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
    Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
    Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
    Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL
    Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S15-7. PubMed ID: 12409058
    [No Abstract]   [Full Text] [Related]  

  • 29. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
    Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
    Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers.
    Heemskerk-Gerritsen BA; Kriege M; Seynaeve C
    JAMA; 2010 Dec; 304(24):2695; author reply 2695-6. PubMed ID: 21177502
    [No Abstract]   [Full Text] [Related]  

  • 32. Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis.
    Norum J; Hagen AI; Maehle L; Apold J; Burn J; Møller P
    Eur J Cancer; 2008 May; 44(7):963-71. PubMed ID: 18362067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oophorectomy in carriers of BRCA mutations.
    Anderson WF; Brawley OW; Chang S
    N Engl J Med; 2002 Sep; 347(13):1037-40; author reply 1037-40. PubMed ID: 12353512
    [No Abstract]   [Full Text] [Related]  

  • 34. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 35. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
    Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
    [No Abstract]   [Full Text] [Related]  

  • 36. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
    van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
    J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic surgery recommended for BRCA1 carriers.
    Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
    [No Abstract]   [Full Text] [Related]  

  • 39. Timing of prophylactic hysterectomy-oophorectomy, mastectomy, and microsurgical breast reconstruction in BRCA1 and BRCA2 carriers.
    Khansa I; Wang D; Coriddi M; Tiwari P
    Microsurgery; 2014 May; 34(4):271-6. PubMed ID: 24123194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.